Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis

SR Susai; C Healy; D Mongan; M Heurich; JF Byrne; M Cannon; G Cagney; K Wynne; C Markulev; MR Schäfer; M Berger; N Mossaheb; M Schlögelhofer; S Smesny; IB Hickie; GE Berger; EYH Chen; L de Haan; DH Nieman; M Nordentoft; A Riecher-Rössler; S Verma; R Street; A Thompson; AR Yung; B Nelson; PD McGorry; M Föcking; GP Amminger; D Cotter

Journal article

Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis

SR Susai, C Healy, D Mongan, M Heurich, JF Byrne, M Cannon, G Cagney, K Wynne, C Markulev, MR Schäfer, M Berger, N Mossaheb, M Schlögelhofer, S Smesny, IB Hickie, GE Berger, EYH Chen, L de Haan, DH Nieman, M Nordentoft Show all

Translational Psychiatry | SPRINGERNATURE | Published : 2022

DOI: 10.1038/s41398-022-02217-0

Download PDF

Abstract

Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis participants at baseline and 6-months follow-up were included. Plasma protein levels were quantified using mass spectrometry and erythrocyte omega-3 PUFA levels were quantified using gas chromatography. We examined the relationship between change in polyunsaturated PUFAs (between baseline and 6-month follow-up) and follow-up plasma proteins. Using mediation analysis, we investigated whether plasma pr..

View full abstract

University of Melbourne Researchers

Connie Markulev Author

Maximus Berger Author

Rebekah Street Author

Andrew Thompson Author

Related Projects (4)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

LIPID BIOLOGY FOR PREDICTION AND PREVENTION OF PSYCHOTIC DISORDERS AND PERSISTENT DEPRESSION IN YOUNG PEOPLE

My vision for the next 5 years is to establish ω-3PUFAs as a first-line treatment for indicated prevention of psychosis and persistent depre..

MAPPING AND TREATING EARLY CLINICAL STAGES OF MENTAL DISORDERS DURING TRANSITION TO ADULTHOOD

The research proposed in this Fellowship is aimed at young people with emerging mental ill-health. The specific goals and targets are to for..

CLINICAL PREDICTORS OF OUTCOME IN THE ULTRA HIGH RISK FOR PSYCHOSIS ("PRODROMAL") POPULATION

This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psy..

Grants

Awarded by Colonial Foundation

Funding Acknowledgements

The NEURAPRO clinical trial (anzctr.org.au Identifier 12608000475347) was supported by the Stanley Medical Research Institute (Grant No. 07TGF-1102 [to PDM, GPA, and BN]), National Health and Medical Research Council (NHMRC) Australia (Grant No. 566529 [to PDM, IBH, ARY, and GPA], NHMRC Senior Research Fellowship Grant No. 1080963 [to GPA], Career Development Fellowship Grant No. 1027532 [to BN], Senior Research Fellowship Grant No. 566593 [to ARY], and Senior Principal Research Fellowship Grant No. 1060996 and Colonial Foundation [to PDM]). This work was supported by an Irish Health Research Board research grant to DC (HRB ILP POR 2019-005), Wellcome Trust Innovation Flagship Award (220438Z/20/Z). This publication has emanated from research supported by Health Research Board (HRB) [to DC, MF] under grant number HRB/HRA/PHR/2015-1293. The research was funded by a research grant from Science Foundation Ireland (SFI) under Grant Number 16/RC/3948 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners.